United States drugmakers must pay Medicare rebates when certain Part B drug prices exceed an international benchmark under the GLOBE Model, which launches Jan. 1, 2027.
The Centers for Medicare & Medicaid Services (CMS), the U.S. agency that runs Medicare, on Sept. 30, 2026 finalized a mandatory model requiring makers of certain Medicare Part B drugs to pay rebates benchmarked to foreign prices, starting Jan. 1, 20271.
The rules behind the model, called the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, take effect on Nov. 30, 20262. The final rule is scheduled for publication in the Federal Register on Oct. 2, 20262.
In short, drugmakers selling certain high-spending, clinic-administered drugs to Medicare will owe extra rebates if their prices sit above what comparable countries pay. Patients in selected areas will pay less coinsurance, and doctors and hospitals will keep billing as usual.
What does the GLOBE Model change?
Part B covers drugs that clinicians usually give in health care settings, such as hospitals and doctors’ offices1. Since the Inflation Reduction Act of 2022, drugmakers already pay Medicare a rebate when they raise prices for certain Part B drugs faster than inflation2. CMS calculates and invoices those rebates2.
GLOBE tests a different way to calculate that rebate for selected drugs. Instead of a domestic benchmark, CMS will use a benchmark drawn from prices paid in economically comparable countries3. When the Medicare price for a model drug exceeds that benchmark, the manufacturer pays a rebate into a Medicare trust fund2.
The GLOBE rebate will never be less than the rebate owed under the existing inflation rebate program2. CMS will invoice it using a step-by-step, or incremental, approach2. The model rests on section 1115A of the Social Security Act, which lets the CMS Innovation Center test new payment models2.
Which countries set the Medicare price benchmark?
The benchmark will come from one of two sources. One is international net pricing data that manufacturers report themselves. The other is pricing data from commercial data providers3.
The reference countries are3:
- Australia, Austria, Belgium, Canada and the Czech Republic
- Denmark, France, Germany, Ireland and Israel
- Italy, Japan, the Netherlands, Norway and South Korea
- Spain, Sweden, Switzerland and the United Kingdom
That is 19 countries in all. CMS cites research from the Department of Health and Human Services finding that U.S. prices for brand-name drugs exceed the average in other developed countries by 422%2. A separate analysis of the top 50 Part B drugs found U.S. prices averaged 211% higher than in comparable countries2.
Which drugmakers must take part?
Participation is mandatory for all manufacturers of Part B drugs that meet the model’s eligibility rules and are not excluded3. Drugmakers can choose to submit their own international net pricing data, but that submission is voluntary3.
Covered drugs are single-source drugs and sole-source biological products already subject to the Part B inflation rebate program2. They must fall into one of these drug categories2:
- antigout agents and cancer drugs (antineoplastics)
- blood products and central nervous system agents
- immune system drugs and bone disease drugs
- eye drugs (ophthalmic agents)
Each drug must also have Medicare Part B spending above $100 million over a 12-month period2. CMS describes the targeted fields as oncology, rheumatology, immunology, ophthalmology and endocrinology3.
CMS alone decides which drugs enter or leave the model, and that choice cannot be appealed2. Rebate amounts also cannot be appealed. Manufacturers may only file a Suggestion of Error, a request to fix a suspected math mistake2.
Which drugs are excluded from the model?
The final rule exempts several groups of products2:
- drugs with a negotiated maximum fair price under the Medicare Drug Price Negotiation Program
- orphan-only drugs, approved only for one or more rare diseases
- products on the FDA list of approved cell and gene therapies
- plasma-derived products
Drugs outside GLOBE
Biosimilars, lower-cost copies of biologic drugs, are excluded. So are the original biologics once a biosimilar enters the U.S. market1. The orphan, plasma and cell and gene therapy exemptions were added after public comments on the proposed rule1.
How will Medicare patients and providers be affected?
The model covers patients in randomly selected ZIP code areas, about 25% of people who have Original Medicare as their primary coverage1. People in Medicare Advantage plans or with employer coverage as their main payer are not included2. CMS picks these patients, and that choice cannot be appealed2.
Who pays on a $100 drug claim, USD
Patients in the selected areas pay lower coinsurance on model drugs. The rule gives an example. On a drug with a $100 allowed amount, coinsurance could fall from 20% to 10%, cutting the patient’s share from $20 to $102. Medicare’s payment to the provider rises from $80 to $90 in that example2.
Hospital outpatient departments, physician practices, surgery centers and pharmacies are not model participants2. They keep buying and billing for the drugs as usual, but must charge the reduced coinsurance when it applies2.
When do the GLOBE rebates and lower costs start?
The schedule runs in stages:
- Nov. 30, 2026: the regulations take effect2.
- Jan. 1, 2027: the model launches with voluntary manufacturer price data submissions2.
- April 1, 2027: five performance years begin and reduced coinsurance applies3.
- March 31, 2032: the performance years and reduced coinsurance end3.
- March 31, 2034: rebate invoicing and reconciliation end1.
GLOBE Model timetable
| Date | What happens |
|---|---|
| Nov. 30, 2026 | Regulations take effect |
| Jan. 1, 2027 | Model launches; voluntary price data submissions open |
| April 1, 2027 | Performance years and reduced coinsurance begin |
| March 31, 2032 | Performance years and reduced coinsurance end |
| March 31, 2034 | Rebate invoicing and reconciliation end |
CMS will calculate, invoice, collect and reconcile rebates over a 7-year payment period that starts April 1, 20272. For drugmakers, the first concrete milestone is Jan. 1, 2027, when the window opens to submit their own international net pricing data2.
Sources
- ↩ CMS Finalizes New Mandatory Drug Payment Model to Deliver Lower Drug Prices for Beneficiaries in Original Medicare Part B | CMS https://www.cms.gov/newsroom/press-releases/cms-finalizes-new-mandatory-drug-payment-model-deliver-lower-drug-prices-beneficiaries-original
- ↩ 2026-20281.pdf https://public-inspection.federalregister.gov/2026-20281.pdf
- ↩ GLOBE (Global Benchmark for Efficient Drug Pricing) Model | CMS https://www.cms.gov/priorities/innovation/innovation-models/globe